Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Srv5.5
Survodutide – Forschung
Überwiegend Mechanismus / Beobachtung
12 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Survodutide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2024–2026 mit einer typischen Studiengröße von 413 Teilnehmenden.
Basierend auf 12 Studien · 2 Meta-Analysen · 5 RCTs · 5,014 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Weight managementDie Phase-2-Dosis von 4,8 mg führte zu einem durchschnittlichen Gewichtsverlust von ~-14,9 % nach 46 Wochen; die Phase-3-Studie SYNCHRONIZE-1 bestätigte ~12-13 % nach 76 Wochen · Fortschreitend über 24-76 Wochen
Überwiegend Mechanismus / Beobachtung10 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung7 Studien
Liver fat, MASH & fibrosisIn einer 48-wöchigen Phase-2-Studie zu MASH/Fibrose zeigte sich bei bis zu 62 % (4,8 mg) gegenüber 14 % unter Placebo eine histologische MASH-Verbesserung ohne Verschlechterung der Fibrose; die Phase-3-Studie SYNCHRONIZE-MASLD erreichte ihren Endpunkt · Bis Woche 48
Überwiegend Mechanismus / Beobachtung6 Studien
Glucose & glycemic controlDosisabhängige HbA1c-Senkungen bei Typ-2-Diabetes (gepooltes HbA1c -0,66 % gegenüber Placebo) · Bis Woche 16-46
Überwiegend Mechanismus / Beobachtung6 Studien
Aktives Forschungsgebiet
12 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
1Meta-Analysen=1,667 · large study2026
Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement, indicating potential weight-loss-independent anti-fibrotic pathways.
Banerjee M, Pal R, Pal S. · Diabetes, obesity & metabolism (2026)
Meta-regression investigated the impact of percentage weight loss and baseline covariates on the proportion of individuals achieving histological end-points.
All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I 2 = 0%).
For MASH resolution, dose-dependent effects led to significant heterogeneity (I 2 = 73%), with lower-dose Semaglutide demonstrating no benefits and Dapagliflozin showing benefits in the F2-F3 subgroup only on sensitivity analysis.
At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2%... in the 3.6-mg group, -13.0%... in the 6.0-mg group, and -5.4%... in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).
le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. · N Engl J Med (2026)
Phase-3 double-blind RCT (n=725) of once-weekly subcutaneous survodutide 3.6/6.0 mg vs placebo over 76 weeks in adults with obesity WITHOUT diabetes — the first reported phase-3 survodutide efficacy trial
Mean weight loss -13.0% (6.0 mg) and -12.2% (3.6 mg) vs -5.4% placebo (treatment-regimen estimand); both co-primary endpoints met
Phase-3 weight loss (~12-13%) came in below the ~14.9% top-dose phase-2 planned-treatment figure, reflecting the more conservative treatment-regimen estimand and high placebo response
In total, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC using the efficacy estimand (P < 0.0001; treatment regimen estimand: 68.5% versus 28.6%, respectively; P < 0.0001). Mean percentage change in body weight was -12.2% with survodutide and -1.0% with placebo using the efficacy estimand.
Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ; SYNCHRONIZE-MASLD Investigators. · Nat Med (2026)
Phase-3 double-blind RCT (n=216, randomized 2:1) of once-weekly subcutaneous survodutide 6.0 mg vs placebo over 48 weeks in adults with obesity and at-risk MASLD (MRI-PDFF/biopsy-defined)
Both co-primary endpoints met: ≥30% liver-fat (MRI-PDFF) reduction in 84.2% vs 24.3% placebo (efficacy estimand), and weight -12.2% vs -1.0% placebo
Extends the phase-2 MASH biopsy signal to a phase-3 imaging-based liver-fat endpoint
We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. · Endocrine reviews (2026)
Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects.
Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery.
This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide.
Balancing pharmacologic innovation with sustainable, equitable implementation remains the defining challenge ahead.
Lempesis IG, Dalamaga M. · Metabolism open (2026)
The amylin pathway has re-emerged through long-acting analogs (cagrilintide, eloralintide) and unimolecular co-agonists (amycretin), achieving weight reductions up to 24% via distinct neuroendocrine circuits.
Collectively, these advances signal a shift from appetite-centric weight loss toward integrated metabolic, neuroendocrine, and body-composition-focused disease modification.
The next epoch of obesity pharmacotherapy will be defined by multi-receptor strategic combinations, targeted approaches to preserve lean mass, and personalized treatment algorithms.
Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R. · N Engl J Med (2024)
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Primary endpoint met: histologic MASH improvement without worsening fibrosis in up to 62% (4.8 mg) vs 14% placebo
≥30% liver-fat reduction in 57-67% of treated groups vs 14% placebo; fibrosis improvement by ≥1 stage in 34-36% vs 22% placebo
Mean (95% CI) changes in bodyweight from baseline to week 46 were -6.2% (0.6 mg); -12.5% (2.4 mg); -13.2% (3.6 mg); -14.9% (4.8 mg); -2.8% (placebo). All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. · Lancet Diabetes Endocrinol (2024)
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-dependent weight loss reaching -14.9% at 4.8 mg (planned-treatment) vs -2.8% placebo at week 46
Adverse events in 91% of survodutide vs 75% placebo, primarily gastrointestinal (75% vs 42%); high discontinuation reduced the completer population
Survodutide reduced HbA1c levels and bodyweight after 16 weeks of treatment in participants with type 2 diabetes.
Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. · Diabetologia (2024)
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Dose-dependent HbA1c reductions with survodutide vs placebo
Gastrointestinal adverse events were the most common, consistent with the incretin class
Survodutide significantly reduced HbA1c (WMD: -0.66%), body weight (WMD: -6.7 kg) and waist circumference (WMD: -7.09 cm)... however, it is crucial to highlight the significant increase in gastrointestinal AEs and the associated risk of treatment discontinuation.
Xiao YJ, Yu S, Zhang YL, Chen J, Liu YQ, Liu XL, Sun CF, Deng CL. · Diabetes Obes Metab (2025)
Systematic review and meta-analysis of 6 RCTs (n=1272) of survodutide vs placebo on glycemic control and weight
Pooled HbA1c -0.66%, fasting glucagon -7 pmol/L, bodyweight -6.7 kg and waist circumference -7.09 cm vs placebo, with modest improvements in BMI, lipids and blood pressure
Greater effects at total weekly doses >2.4 mg and durations >16 weeks
Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression.
Kaya E, Yilmaz Y, Alkhouri N. · Expert Opin Investig Drugs (2024)
Review of survodutide's pharmacology, phase-1/phase-2 efficacy and safety in obesity and MASH
Frames the dual GCGR/GLP-1R mechanism as potentially superior to GLP-1 mono-agonism for MASH and fibrosis regression — an area where GLP-1 agonists alone have unproven fibrosis benefit
Notes generally manageable, primarily gastrointestinal adverse effects
Survodutide is generally tolerable in people with compensated or decompensated cirrhosis, does not require pharmacokinetic-related dose adjustment, and may improve liver-related non-invasive tests, supporting its investigation for MASH-related cirrhosis.
Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takács I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R. · J Hepatol (2024)
Multinational, non-randomized, open-label phase-1 trial of subcutaneous survodutide in people with Child-Pugh A/B/C cirrhosis vs matched healthy/overweight controls (single-dose cohorts n=41)
Pharmacokinetics did not require dose adjustment for cirrhosis severity; survodutide was generally tolerable including in decompensated cirrhosis
Associated reductions in liver-fat content, markers of liver fibrosis and bodyweight
Phase 2 trials have demonstrated weight loss up to 18.7% and HbA1c reductions up to -1.71%, outperforming semaglutide for weight outcomes while maintaining comparable glycemic efficacy... Adverse events, primarily gastrointestinal intolerance and modest heart rate increases, remain important limitations.
Arun AJ, Darji B, Baig M, Frishman WH, Aronow WS. · Cardiol Rev (2025)
Cardiometabolic-focused review summarising survodutide's broad metabolic effects across obesity, type 2 diabetes and MASH
Cites phase-2 weight loss up to 18.7% and HbA1c reductions up to -1.71%, with hepatic fat reduction and anti-inflammatory signals
Flags modest heart-rate increases and GI intolerance driving higher discontinuation than comparators as key limitations